Compare Dover Corp (DOV) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dover Corp vs Heron Therapeutics Inc — how do they compare? Dover Corp trades at $188.83 (market cap $25.45B), while Heron Therapeutics Inc trades at $0.41 (market cap $68.01M). The key difference: Dover Corp is far larger — about 374.2× Heron Therapeutics Inc's market cap, and Dover Corp pays a 1.11% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dover Corp for 73 Days and Heron Therapeutics Inc for 35 Days on average.
| DOV | HRTX | |
|---|---|---|
Market Cap | $25.45B | $68.01M |
Volume | 661,758 | 1,891,941 |
Sector | Industrials | Health |
52-Week High | $233.31 | $1.49 |
52-Week Low | $161.16 | $0.27 |
Typical Hold Time | 73 Days | 35 Days |
Enterprise Value | $26.95B | $174.75M |
Dividend Yield | 1.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dover Corporation (DOV) trades at $188.96, up 0.36% today, with a bearish technical signal from moving averages but neutral oscillators. The company maintains solid fundamentals, with a P/E of 22.85 and net income margin of 13.48%, while consistently beating EPS estimates in recent quarters. Recent news highlights product launches and strategic acquisitions, such as the completion of Cloeren's purchase, reinforcing growth initiatives.
The outlook is positive, supported by a strong analyst consensus with a $243.20 price target and no sell ratings. Risks include market volatility and execution of acquisition integration, but robust cash flow and dividend history provide stability. Upside potential hinges on continued earnings outperformance and sector tailwinds.
HRTX trades at $0.3582, down 8.15% today, with a bullish technical signal from moving averages but mixed earnings. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates, continuing a trend of net losses. Analyst sentiment remains strongly positive with 89% buy ratings, though Zacks issued a Strong Sell rating in July 2026.
The outlook hinges on revenue stabilization and path to profitability. Investment opportunity lies in analyst optimism and product sales growth, but risks include persistent losses, high valuation multiples, and competitive pressures in the biotechnology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
